

सं. / No. 50014/03/2020-CDN

भारत सरकार / Government of India

रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers

औषध विभाग / Department of Pharmaceuticals

शास्त्री भवन, नई दिल्ली / Shastri Bhawan, New Delhi

Dated: 11th July, 2023

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of June, 2023-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of June, 2023 for information.



(Shamim Uddin Ansari)

Under Secretary to the Govt. of India

Tel. 011-23387920

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. Sr. PPS to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals

1. Important policy decisions taken and major achievements during the month of June 2023:

A. National Pharmaceutical Pricing Authority (NPPA):

- i. Retail price fixed for 23 new drugs and ceiling prices fixed for 18 scheduled formulations under NLEM 2022 in the 113th Authority Meeting held on 26.5.2023, which were notified vide different S.O.s dated 08.6.2023.
- ii. Further, retail prices fixed for 51 new drugs and ceiling prices fixed for 2 scheduled formulations under NLEM 2022 during 114th Authority Meeting held on 19.6.2023, which were notified vide S.O.s dated 28.6.2023. The details of prices fixed in the financial year 2023-2024 are as under:

S. No.	Prices fixed/ Notified under Revised Schedule I (NLEM 2022)	During the month of 1 st June, 2023 to 30 th June 2023	Cumulative from 1 st April, 2023 to 30 th June 2023
1.	Retail Price of 'New Drug'	74	89
2.	i. Fixation of ceiling Price under revised scheduled-I (NLEM 2022) of DPCO, 2013 ii. Ceiling price under para 19 of DPCO, 2013 (NLEM 2022)	19 01	40

- iii. Review application dated 20.1.2023 filed by M/s Dales Laboratories Private Limited (Applicant) under Para 31 of the DPCO, 2013 against price fixation order issued vide S.O. No. 193(E) dated 11.1.2023 by the NPPA for retail price of Paracetamol 500 mg+ Phenylephrine hydrochloride 5 mg + Diphenhydramine 25 mg + Caffeine (Anhydrous) 30 mg tablet, was disposed of vide DoP order no. 31015/22/2023- Pricing (E-23303) dated 20.6.2023 in favour of NPPA.
- iv. On the basis of Monitoring & Enforcement activities, sixteen (16) Preliminary Notice (PN) were issued.
- v. **Rs. 11,93,88,574.50/-** was received during the month towards overcharged amount.
- vi. NPPA through Price Monitoring and Resource Units (PMRUs) in 23 States/UTs conducted four market surveys during June 2023 to assess the availability of COVID management drugs including 6 medical devices.
- vii. NPPA is encouraging use of e-office to reduce the use of paper. In line with this effort, 162 new e-files were opened during the month.

B. National Institutes of Pharmaceutical Education & Research (NIPERs):

Major Achievements of NIPERs during the month are as under:

- i. Out of 256 research papers published during the current financial year, 79 papers have been published in the month of June 2023.
- ii. Out of 14 Patents filed during the current financial year, 7 patent were filed in the month of May 2023.
- iii. Out of the 11 MoUs signed during the current financial year, 3 MoUs have been signed in the month of May, 2023.

- iv. As per National Institutional Ranking Framework (NIRF) of the Ministry of Education, under the 'Pharmacy' category, six NIPERs are amongst the top thirty-three pharmacy Institute in the country and **NIPER-Hyderabad has achieved first position in the NIRF Ranking 2023** in Pharmacy category all over India.
- v. The Scheme for Promotion of Research and Innovation in Pharma-Med Tech (PRIP) and the National Policy on Research & Development, and Innovation in the Pharma-MedTech Sector were considered by ETG in its meeting held on 24.05.2023. The minutes of the meeting have been received on 31.05.2023. Based on suggestions made therein, revised Scheme with approval of HMCF, will be sent to Cabinet Secretariat/ PMO for placing before the Cabinet.
- vi. The National Policy on Research & Development and Innovation in the Pharma-MedTech Sector considered by ETG in its meeting held on 24.05.2023. The Minutes of the meeting have been received on 31.05.2023. Based on suggestion made therein, revised FCN with approval of the HMCF was sent to Cabinet Secretariat/PMO for placing before the Cabinet on 21.06.2023.
- vii. All NIPERs organised World Environment day on June 05, 2023.
- viii. All NIPERs celebrated International Yoga Day and Yoga practices on June 21, 2023.

NIPER Mohali:

- i. Celebrated World Environment Day on June 05, 2023.
- ii. Organised a one-week hands on training on HPLC from June 12-16, 2023.
- iii. Organised Pharmaceutical Industrial Training from June 13, 2023 to July 03, 2023.
- iv. Organised Hindi Karyashala on June 14, 2023.
- v. Organised an event on Woman and Child rights and Sexual Abuse on June 20, 2023.
- vi. Organised an event on Enyne Metathesis Approach for the Total Synthesis of Strychnine on June 30, 2023.

NIPER Kolkata:

- i. Organised an event on Flow Chemistry on June 21, 2023.
- ii. Organised an event on Addressed on Marine Sources Macrolide compounds synthesis for resistant bacteria and fungus.

NIPER Guwahati:

- i. Organised Ayurveda healthcare lecture on "Importance of Ayurveda for human wellbeing" on June 16, 2023.

NIPER-Raebareli:

- i. Signed MoU for Collaborative research related to Medicinal Chemistry, Drug Design, to train NIPER Students and faculty support with the IIT, Kanpur on June 02, 2023.

C. International Cooperation:

- i. DoP participated in the 16th Session of India- Austria Joint Economic Commission (JEC) on 12th June, 2023 Vienna through Virtual Mode and the 11th Session of India-Slovak Joint Economic Committee (JEC) on 14th June, 2023 through Virtual Mode. The meeting was held under the Co-chairpersonship of Ms. Nidhi Mani Tripathi, Joint Secretary (Europe) for both the JEC sessions from the Indian side.
- ii. DoP participated in the 1st **Joint Working Group** meeting between India and Kyrgyzstan on **12th June 2023** through virtual mode. The meeting was held under

- the Co-chairmanship of Mr. Lav Agarwal, Additional Secretary, Ministry of Health and Family Welfare from Indian side.
- iii. DoP participated in the Bilateral meetings of Industrial Collaboration Working Group (ICWG) and **Joint Working Group (JWG)** with Taiwan on 15th June, 2023 through virtual mode. The meeting led by Co-chairpersonship of Ms. Manmeet K. Nanda, Joint Secretary, DPIIT from Indian side **discussed the potential areas to strengthen bilateral cooperation in pharmaceuticals.**
 - iv. Meeting with with Department of Pharmaceutical Affairs and Medical Technology, Ministry of Health, Welfare and Sport, Netherlands was organized on 21st June 2023 under chairmanship of Dr. N. Yuvaraj, JS DoP from the Indian side wherein Collaboration between India – Netherlands for equity and affordability of Pharmaceutical Products, supply chain specifically for Vaccine raw materials, Cross boarder investment and partnership to strengthen resilience in global supply chains, Collaboration of NIPERs with Netherlands including development of Center of Excellence (CoE) between NIPERs and concerned counterpart institutions in Netherlands was discussed.
 - v. DoP participated in the **3rd Joint Working Group (JWG) meeting between India and Denmark on 28th June 2023** at New Delhi. The meeting led by Co-chairmanship of Mr. Lav Agarwal, Additional Secretary, Ministry of Health and Family Welfare from Indian side and Ms. Dorte Bech Vizard, Deputy Permanent Secretary, Patient Safety, Medicines and Global Health, Ministry of Interior and Health Pharmaceutical Cooperation, Medical Devices and Diagnostics from the Denmark side. Wherein, potential areas to strengthen Pharmaceuticals Cooperation, Medical Devices and Diagnostics was discussed.

D. Schemes:

(i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

- 28 new PMBJP Kendras have been opened during June 2023 and the cumulative number of Kendras has been reached to 9512 all over India.
- Sales under PMBJP at MRP Value was Rs. 113.24 Crore and saving to common man was 679.00 Crore (Approx.) during the month of June, 2023.
- The cumulative figure of product basket reached to 1800 Dugs and 285 Surgical instruments during the month of June, 2023.
- Sale of Suvidha Sanitary Napkins @ Rs. 1/- per pad was Rs. 1.21 Crore during the month June, 2023.
- Department has provided incentive of Rs. 0.27 Crores during the month of June, 2023 to the beneficiaries.

(ii) Status of PLI Schemes:

S. No.	Name of Scheme		Total No. of Application Received*	No. of Applications approved in the month of June 2023	Total no. of applications approved as on date
1.	Production Linked Incentive Scheme for Bulk Drug (Last EC Meeting held on 09.06.2023 on PLI Bulk Drugs)	Round 1	215	0	39
		Round 2	24	0	08
		Round 3	09	0	03
		Round 4	01	0	01
		Total	249	0	51
2.		Round 1	28	0	13
		Round 2	14	0	08

	Production Linked Incentive Scheme for Medical Device (Last EC Meeting held on 09.06.2023 on Medical Devices)	Round 3	18	0	05
		Round 4	04*	0	0
		Total	64	0	26
3	Production Linked Incentive Scheme for Pharmaceuticals		278	0	55

*In PLI Medical Devices round –IV application window, four applications have been received which are under examination as Empowered Committee meeting held on 09.06.2023.

E. FDI inflow approved during this month: NIL

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

3. No. of cases of ‘sanction for prosecution’ pending for more than three months:

NIL

4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):

- As regards SCDPM Portal is concerned, inputs received from various Sections have been compiled and uploaded on the Portal for the month of May 2023, within the due date.
- As per DARPG Special Report for the month of May 2023 on CPGRAMS, the Department is ranked at 13 among all Ministries/Departments, with Grievance Redressal Assessment and Index (GRAI) score of 0.67. The report has been further taken for review with respect to the Jan Aushadhi Scheme.

6. Status of Rationalization of Autonomous Bodies:

Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

(i) Department of Pharmaceuticals:

S. No.	Name of the posts	Sanctioned Strength	In-position	Vacancy	Group
1	Director/DS	06	04	02	A

2	Under Secretary	10	08	02	A
3	Principal Private Secretary	02	0	02	A
4	Section Officer	16	03	13	B
	Total	34	15	19	

(ii) Public Sector Undertakings:

(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):

S. No.	Designation	Vacant Positions
1	Senior Manager	06
2	Deputy General Manager	03
3	General Manager	06
	Total	15

(b) Hindustan Antibiotics Limited (HAL) (under strategic sale):

S.No.	Designation	Vacant Positions
1	CGM	3
2	GM	3
3	DGM	12
4	Manager	20
	Total	38

(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL) (under strategic sale):

S.No.	Designation	Vacant Positions
1	Manager (Legal)	1
2	DGM (Marketing)	1
3	Sr. Manager (Purchase)	1
4	DGM (Finance)	1
5	Assistant Manager (Company Secretary)	1
6	Factory Head (DGM/AGM)	2
7	AGM (QA/QC)	1
	Total	8

(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL

(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) : NIL

9. List of cases in which ACC directions have not been complied with:

NIL

10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:

(i)	Pending at beginning of the month	:	8
(ii)	Received during the month	:	1
(iii)	Disposed of during the month	:	0
(iv)	Pending at end of the month	:	9
